9 Result(s)

Article

Cooperation of BRAF^F595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling

Activating BRAF mutations, in particular V600E/K, drive many cancers and are considered mutually exclusive with mutant RAS, whereas inactivating BRAF mutations in the D⁵⁹⁴F⁵⁹⁵G⁵⁹⁶ motif cooperate with RAS via par...

M Kordes, M Röring, C Heining, S Braun, B Hutter, D Richter, C Geörg, C Scholl… in Leukemia (2016)

Article

Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q

Imbalances in chromosome 11q occur in approximately 30% of primary neuroblastoma and are associated with poor outcome. It has been suggested that 11q loss constitutes a distinct clinico-genetic neuroblastoma s...

M Fischer, T Bauer, A Oberthür, B Hero, J Theissen, M Ehrich, R Spitz, R Eils… in Oncogene (2010)

Article

The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence

We found that composition of cell subsets within the CD34+ cell population is markedly altered in chronic phase (CP) chronic myeloid leukemia (CML). Specifically, proportions and absolute cell counts of common...

I Bruns, A Czibere, J C Fischer, F Roels, R-P Cadeddu, S Buest, D Bruennert… in Leukemia (2009)

Article

Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma

Cell adhesion molecule 1 (CADM1) is a putative tumour suppressor gene, which is downregulated in many solid tumours. In neuroblastoma, loss of CADM1 expression has recently been found in disseminated tumours with...

S Nowacki, M Skowron, A Oberthuer, A Fagin, H Voth, B Brors, F Westermann… in Oncogene (2008)

Article

Molecular signature of CD34⁺ hematopoietic stem and progenitor cells of patients with CML in chronic phase

In this study, we provide a molecular signature of highly enriched CD34+ cells from bone marrow of untreated patients with chronic myelogenous leukemia (CML) in chronic phase in comparison with normal CD34+ ce...

E Diaz-Blanco, I Bruns, F Neumann, J C Fischer, T Graef, M Rosskopf, B Brors… in Leukemia (2007)

Article

Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients

Although the selective tyrosine kinase inhibitor imatinib is successfully used in the treatment of chronic myeloid leukemia (CML), inherent mechanisms confer primary resistance to leukemic patients. In order t...

O Frank, B Brors, A Fabarius, L Li, M Haak, S Merk, U Schwindel, C Zheng… in Leukemia (2006)

Article

Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis

Despite recent success in the treatment of early-stage disease, blastic phase (BP) of chronic myeloid leukemia (CML) that is characterized by rapid expansion of therapy-refractory and differentiation-arrested ...

C Zheng, L Li, M Haak, B Brors, O Frank, M Giehl, A Fabarius, M Schatz… in Leukemia (2006)

Article

Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib

F Neumann, N Teutsch, S Kliszewski, S Bork, U Steidl, B Brors, N Schimkus… in Leukemia (2005)